» Authors » Murat Digicaylioglu

Murat Digicaylioglu

Explore the profile of Murat Digicaylioglu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 844
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan J, Digicaylioglu M, Wang S, Dresselhuis J, Dedhar S, Mills J
Heliyon . 2019 Aug; 5(8):e02294. PMID: 31463398
Insulin promotes neuronal survival by activating a phosphatidylinositol 3-kinase (PI 3-kinase)/AKT-dependent signaling pathway and reducing caspase activation. We investigated a role for integrin-linked kinase (ILK) in insulin-mediated cell survival in...
2.
Garling R, Watts L, Sprague S, Digicaylioglu M
Neural Regen Res . 2018 Apr; 13(3):434-439. PMID: 29623927
The mechanistic target of rapamycin (mTOR) is an intracellular protein kinase that functions as an energy and nutrient sensor in the cellular microenvironment of neurons. Modulation of mTOR is vital...
3.
Solaroglu I, Digicaylioglu M, Keles G, Zhang J
Curr Med Chem . 2015 Feb; 22(10):1302-9. PMID: 25666797
Granulocyte-colony stimulating factor (G-CSF) has a multimodal neuroprotective profile and the cumulative preclinical data from numerous translational studies statistically confirmed the efficacy of G-CSF as a treatment option in ischemic...
4.
Garling R, Watts L, Sprague S, Fletcher L, Jimenez D, Digicaylioglu M
Neural Regen Res . 2015 Jan; 9(21):1891-6. PMID: 25558238
There are currently no federally approved neuroprotective agents to treat traumatic brain injury. Progesterone, a hydrophobic steroid hormone, has been shown in recent studies to exhibit neuroprotective effects in controlled...
5.
Fletcher L, Isgor E, Sprague S, Williams L, Alajajian B, Jimenez D, et al.
BMC Neurosci . 2013 Dec; 14:158. PMID: 24359611
Background: Insulin-like growth factor binding protein-2 (IGFBP-2) regulates the bioavailability, transportation, and localization of insulin-like growth factor-I (IGF-I), an effective neuroprotectant in animal stroke models especially when administered intranasally. Therefore,...
6.
Ziu M, Fletcher L, Savage J, Jimenez D, Digicaylioglu M, Bartanusz V
Spine J . 2013 Nov; 14(2):353-60. PMID: 24269082
Background Context: MicroRNAs, a class of small nonprotein-coding RNAs, are thought to control gene translation into proteins. The latter are the ultimate effectors of the biochemical cascade occurring in any...
7.
Fletcher L, Evans T, Watts L, Jimenez D, Digicaylioglu M
PLoS One . 2013 Jul; 8(7):e68281. PMID: 23861877
Ischemic stroke is the leading cause of serious, long-term adult disability and is associated with sensorimotor and cognitive impairments due to neuronal degeneration. Currently, recombinant tissue plasminogen activator (rTPA) is...
8.
Digicaylioglu M
Methods Mol Biol . 2013 Mar; 982:175-86. PMID: 23456869
The search for potential drugs to treat neurodegenerative diseases has been intense in the last two decades. Among many candidates, erythropoietin (EPO) was identified as a potent protectant of neurons...
9.
Watts L, Sprague S, Zheng W, Garling R, Jimenez D, Digicaylioglu M, et al.
J Neurotrauma . 2012 Oct; 30(1):55-66. PMID: 23046422
Traumatic brain injury (TBI) is the leading cause of death and disability in children and young adults. Neuroprotective agents that may promote repair or counteract damage after injury do not...
10.
Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M
Ann Neurol . 2011 Jun; 70(2):194-206. PMID: 21674586
The blood-spinal cord barrier (BSCB) is the functional equivalent of the blood-brain barrier (BBB) in the sense of providing a specialized microenvironment for the cellular constituents of the spinal cord....